查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607228

妇科癌症药物市场：按适应症、药物类别、分销管道、最终用户划分 - 全球预测 2025-2030

Gynecological Cancer Drugs Market by Indication (Cervical Cancer, Chemotherapy, Ovarian & Fallopian Tube Cancer), Drug Class (Alkylating Agent, Anthracyclines, Antitumor Antibiotic), Distribution Channel, End-users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年妇科癌症药物市值为93.6亿美元，预计到2024年将达到103.5亿美元，复合年增长率为11.95%，到2030年将达到206.5亿美元，预计将达到1000万美元。

妇科癌症药物是一种旨在治疗女性生殖系统癌症的癌症药物，例如子宫颈癌、卵巢癌、子宫内膜癌、阴道癌和外阴癌。全球妇科癌症的高负担凸显了对这些药物的需求，这需要有效的治疗方案来提高受影响妇女的生存率和生活品质。这些药物用于癌症治疗的各个阶段，从化疗和标靶治疗到维持和安宁疗护，最终用途主要在医院、癌症治疗中心和专科诊所。主要的促进成长因素包括由于老化和生活方式的改变导致妇科癌症盛行率上升、医疗基础设施的进步以及政府和非政府组织加强对癌症认识和筛检的活性化。市场参与者的机会在于精准医疗和新型标靶治疗的开拓，其中生物标记识别和个人化治疗方法是有前景的领域。然而，高昂的药物开发成本、严格的监管政策以及某些治疗方法可能出现的副作用等挑战构成了重大障碍。低收入地区的意识和可及性有限，进一步限制了市场扩张。该领域的创新可能会集中在用于癌症早期检测的更好的诊断工具，以及用于提高治疗效果的免疫疗法和联合治疗。製药公司、研究机构和医疗保健提供者之间的合作也可以促进创新。市场仍然充满活力，持续的研究和综合治疗通讯协定的需求推动了竞争的加剧。对于相关人员来说，竞争优势包括投资于研发以创造更有效和更容易获得的治疗方案、寻求技术转移伙伴关係以及可能产生的适合当地需求的行销策略。保持技术敏捷性和遵守法规对于这个重要医疗保健产业的持续成长至关重要。

主要市场统计
基准年[2023] 93.6亿美元
预测年份 [2024] 103.5亿美元
预测年份 [2030] 206.5亿美元
复合年增长率（%） 11.95%

市场动态：快速发展的妇科癌症药物市场的关键市场洞察

供需的动态交互作用正在改变妇科癌症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 各种妇科癌症的盛行率不断上升
    • 女性老化和保健意识的提高
    • 政府努力开发治疗和预防药物
  • 市场限制因素
    • 妇科癌症药物配方相关的高成本和品质问题
  • 市场机会
    • 卵巢癌新疗法的开发与引进
    • 医疗基础设施现代化和新药投资增加
  • 市场挑战
    • 与药品核准相关的严格法律规范

波特五力：驾驭妇科癌症药物市场的策略工具

波特五力是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对妇科癌症药物市场的影响

外部宏观环境因素对妇科癌症药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解妇科癌症治疗药物市场竞争状况

对妇科癌症药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 妇科癌症药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估妇科癌症药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘妇科癌症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对妇科癌症药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 各种妇科癌症发生率上升
      • 老年女性人口增加和医疗保健意识不断提高
      • 政府努力开发治疗和预防药物
    • 抑制因素
      • 妇科癌症药物配方相关的高成本和品质问题
    • 机会
      • 卵巢癌新治疗方法的开发和引入
      • 增加对现代化医疗基础设施和新药的投资
    • 任务
      • 与药品核准相关的严格法规结构
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依适应症分類的妇科肿瘤药物市场

  • 子宫颈癌
  • 化疗
  • 卵巢和输卵管癌
  • 子宫癌
  • 阴道癌
  • 外阴癌

第七章依药物类别分類的妇科癌症药物市场

  • 烷化剂
  • 细胞週期蛋白
  • 抗肿瘤抗生素
  • 植物生物碱

第八章妇科肿瘤药物市场：依通路划分

  • 电子商务
  • 医院药房
  • 零售药房

第九章妇科癌症药物市场：依最终使用者分类

  • 诊所
  • 医院
  • 专业癌症治疗中心

第十章 美洲妇科癌症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区妇科肿瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲妇科癌症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apotex Pharmaceutical Holdings Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.
  • VBL Therapeutics, Inc.
Product Code: MRR-DD0700E81D10

The Gynecological Cancer Drugs Market was valued at USD 9.36 billion in 2023, expected to reach USD 10.35 billion in 2024, and is projected to grow at a CAGR of 11.95%, to USD 20.65 billion by 2030.

Gynecological cancer drugs encompass a specific segment of oncology pharmaceuticals aimed at treating cancers of the female reproductive system, including cervical, ovarian, uterine, vaginal, and vulvar cancers. The necessity for these drugs is underscored by the significant global burden of gynecological cancers, which demand effective treatment options to improve survival rates and quality of life for affected women. These medications are utilized across various stages of cancer management, from chemotherapy and targeted therapy to maintenance and palliative care, with end-use primarily in hospitals, cancer treatment centers, and specialized clinics. Key growth drivers include a rising prevalence of gynecological cancers due to factors like aging populations and lifestyle changes, advancements in healthcare infrastructure, and increased governmental and NGO initiatives for cancer awareness and screening. Opportunities for market players lie in the development of precision medicine and novel targeted therapies, with biomarker identification and personalized treatment regimens being promising areas. However, challenges such as high drug development costs, stringent regulatory policies, and the potential side effects of some treatments are significant hurdles. Limited awareness and accessibility in lower-income regions further restrict market expansion. Innovations in this sector could focus on immunotherapy and combination therapies that enhance treatment efficacy, alongside better diagnostic tools for early cancer detection. Collaborations between pharmaceutical companies, research institutions, and healthcare providers could also boost innovation. The market remains dynamic, with a competitive landscape driven by ongoing research and the need for comprehensive treatment protocols. For stakeholders, investing in R&D to create more effective and accessible treatment options, exploring partnerships for technology transfer, and tailoring marketing strategies to regional needs can provide competitive advantages. Maintaining technological agility and regulatory compliance will be crucial for sustainable growth in this vital healthcare segment.

KEY MARKET STATISTICS
Base Year [2023] USD 9.36 billion
Estimated Year [2024] USD 10.35 billion
Forecast Year [2030] USD 20.65 billion
CAGR (%) 11.95%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of various gynecological cancers
    • Increasing aging female population and rising healthcare awareness
    • Government initiatives to develop both therapeutic and preventive drugs
  • Market Restraints
    • High cost and quality issues associated with formulation of gynecological cancer drugs
  • Market Opportunities
    • Development and introduction of novel ovarian cancer treatments
    • Increasing investments to modernized healthcare infrastructure and novel drugs
  • Market Challenges
    • Stringent regulatory frameworks associated with approval of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gynecological Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gynecological Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gynecological Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gynecological Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gynecological Cancer Drugs Market

A detailed market share analysis in the Gynecological Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gynecological Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gynecological Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gynecological Cancer Drugs Market

A strategic analysis of the Gynecological Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gynecological Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Apotex Pharmaceutical Holdings Inc., AstraZeneca PLC, Bayer AG, Biocon Limited, Bristol-Myers Squibb Company, Clovis Oncology, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline PLC, ImmunoGen, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc., and VBL Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Gynecological Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Cervical Cancer, Chemotherapy, Ovarian & Fallopian Tube Cancer, Uterine Cancer, Vaginal Cancer, and Vulvar Cancer.
  • Based on Drug Class, market is studied across Alkylating Agent, Anthracyclines, Antitumor Antibiotic, and Plant Alkaloid.
  • Based on Distribution Channel, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on End-users, market is studied across Clinics, Hospitals, and Specialized Cancer Treatment Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of various gynecological cancers
      • 5.1.1.2. Increasing aging female population and rising healthcare awareness
      • 5.1.1.3. Government initiatives to develop both therapeutic and preventive drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and quality issues associated with formulation of gynecological cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development and introduction of novel ovarian cancer treatments
      • 5.1.3.2. Increasing investments to modernized healthcare infrastructure and novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks associated with approval of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gynecological Cancer Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Cervical Cancer
  • 6.3. Chemotherapy
  • 6.4. Ovarian & Fallopian Tube Cancer
  • 6.5. Uterine Cancer
  • 6.6. Vaginal Cancer
  • 6.7. Vulvar Cancer

7. Gynecological Cancer Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alkylating Agent
  • 7.3. Anthracyclines
  • 7.4. Antitumor Antibiotic
  • 7.5. Plant Alkaloid

8. Gynecological Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Gynecological Cancer Drugs Market, by End-users

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals
  • 9.4. Specialized Cancer Treatment Centers

10. Americas Gynecological Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gynecological Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gynecological Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Alnylam Pharmaceuticals, Inc.
  • 4. Amgen Inc.
  • 5. Apotex Pharmaceutical Holdings Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. Biocon Limited
  • 9. Bristol-Myers Squibb Company
  • 10. Clovis Oncology
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Genentech Inc.
  • 15. GlaxoSmithKline PLC
  • 16. ImmunoGen, Inc.
  • 17. Johnson & Johnson Services, Inc.
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Sanofi SA
  • 22. Takeda Pharmaceutical Co., Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. TherapeuticsMD Inc.
  • 25. VBL Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN & FALLOPIAN TUBE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLANT ALKALOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALIZED CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023